Acetylsalicylic Acid

EGFR Gene Mutation

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

30 Active assets in the EGFR Gene Mutation cohort.

Asset / Sponsor	Phase	Rating
Osimertinib Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	Phase 3	BB
Gefetinib China Medical University Hospital	Phase 2/3	BB
Carboplatin Guangdong Provincial People's Hospital	Phase 3	B
CIS-DIAMMINEDICHLOROPLATINUM II Sichuan Cancer Hospital and Research Institute	Phase 3	B
Cyclophosphamide Hideho Okada, MD, PhD	Phase 2	B